These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 22574973)

  • 1. Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
    Bissantz C; Bohnert C; Hoffmann T; Marcuz A; Schnider P; Malherbe P
    J Med Chem; 2012 Jun; 55(11):5061-76. PubMed ID: 22574973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.
    Blaney FE; Raveglia LF; Artico M; Cavagnera S; Dartois C; Farina C; Grugni M; Gagliardi S; Luttmann MA; Martinelli M; Nadler GM; Parini C; Petrillo P; Sarau HM; Scheideler MA; Hay DW; Giardina GA
    J Med Chem; 2001 May; 44(11):1675-89. PubMed ID: 11356103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures.
    Malherbe P; Kratzeisen C; Marcuz A; Zenner MT; Nettekoven MH; Ratni H; Wettstein JG; Bissantz C
    J Med Chem; 2009 Nov; 52(22):7103-12. PubMed ID: 19817444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia.
    Catalani MP; Alvaro G; Bernasconi G; Bettini E; Bromidge SM; Heer J; Tedesco G; Tommasi S
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6899-904. PubMed ID: 21974957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors.
    Engberg S; Ahlstedt I; Leffler A; Lindström E; Kristensson E; Svensson A; Påhlman I; Johansson A; Drmota T; von Mentzer B
    Biochem Pharmacol; 2007 Jan; 73(2):259-69. PubMed ID: 17097619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).
    Giardina GA; Raveglia LF; Grugni M; Sarau HM; Farina C; Medhurst AD; Graziani D; Schmidt DB; Rigolio R; Luttmann M; Cavagnera S; Foley JJ; Vecchietti V; Hay DW
    J Med Chem; 1999 Mar; 42(6):1053-65. PubMed ID: 10090788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution and pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors in the central nervous system of the rhesus monkey.
    Nagano M; Saitow F; Haneda E; Konishi S; Hayashi M; Suzuki H
    Br J Pharmacol; 2006 Feb; 147(3):316-23. PubMed ID: 16331282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.
    Malherbe P; Knoflach F; Hernandez MC; Hoffmann T; Schnider P; Porter RH; Wettstein JG; Ballard TM; Spooren W; Steward L
    Br J Pharmacol; 2011 Feb; 162(4):929-46. PubMed ID: 21039418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
    Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
    Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterization.
    Malherbe P; Knoflach F; Marcuz A; Bohnert C; Weber M; Knust H; Ratni H; Spooren W; Ballard TM; Bissantz C
    Neuropharmacology; 2014 Nov; 86():259-72. PubMed ID: 25107588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
    Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
    J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework.
    Giardina GA; Sarau HM; Farina C; Medhurst AD; Grugni M; Raveglia LF; Schmidt DB; Rigolio R; Luttmann M; Vecchietti V; Hay DW
    J Med Chem; 1997 Jun; 40(12):1794-807. PubMed ID: 9191956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3.
    Leffler A; Ahlstedt I; Engberg S; Svensson A; Billger M; Oberg L; Bjursell MK; Lindström E; von Mentzer B
    Biochem Pharmacol; 2009 May; 77(9):1522-30. PubMed ID: 19426690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that the proposed novel human "neurokinin-4" receptor is pharmacologically similar to the human neurokinin-3 receptor but is not of human origin.
    Sarau HM; Mooney JL; Schmidt DB; Foley JJ; Buckley PT; Giardina GA; Wang DY; Lee JA; Hay DW
    Mol Pharmacol; 2000 Sep; 58(3):552-9. PubMed ID: 10953048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
    Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
    Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands.
    Peters JU; Hoffmann T; Schnider P; Stadler H; Koblet A; Alker A; Poli SM; Ballard TM; Spooren W; Steward L; Sleight AJ
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3405-8. PubMed ID: 20430616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
    Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
    Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Human NK inhibitory and activating receptors that bind to human leukocyte antigens (HLA) regulate NK cells and T cells].
    Ikeda H; Coulie PG
    Tanpakushitsu Kakusan Koso; 1997 Nov; 42(15):2510-21. PubMed ID: 9391340
    [No Abstract]   [Full Text] [Related]  

  • 19. Modification of the potent peptide FK888 with unusual aminoacids: effects on activity on neurokinin receptors.
    Caliendo G; Greco G; Grieco P; Perissutti E; Santagada V; Calignano A; Mancuso F; Novellino E
    Farmaco; 1996 Mar; 51(3):197-201. PubMed ID: 8688142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modeling of neurokinin B and tachykinin NK₃ receptor complex.
    Ganjiwale AD; Rao GS; Cowsik SM
    J Chem Inf Model; 2011 Nov; 51(11):2932-8. PubMed ID: 21913652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.